Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways

Overexpression of hepatocyte growth factor (HGF), also called scatter factor (SF), and its receptor c-Met are associated with poor prognosis for cancer patients. In particular, breast cancer cells can produce HGF that acts in a paracrine as well as in an autocrine manner. Therefore, HGF and c-Met are putative targets for cancer therapy. To explore HGF/c-Met signaling in breast cancer, we have generated transgenic mice expressing HGF specifically in mammary epithelium under the transcriptional control of the whey acidic protein (WAP) gene promoter. WAP-HGF transgenic females developed hyperplastic ductal trees and multifocal invasive tumors after several pregnancies, some of which progressed to lung metastases. Tumors produced HGF and displayed phosphorylated c-Met, which correlated with increased Akt as well as c-myc activation. A high growth rate, as demonstrated by Ki67 nuclear antigen staining, and a lack of progesterone receptor were characteristic of the tumors. Immunohistochemical analysis revealed areas of osteopontin (Opn) expression in WAP-HGF tumors and lung metastases in agreement with a previously reported role for Opn in invasive growth. We suggest that these mice may serve as a new breast cancer model for the evaluation of the effects of unscheduled HGF expression in breast cancer.

[1]  C. Birchmeier,et al.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.

[2]  A. Chambers,et al.  The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies , 2001, Journal of Mammary Gland Biology and Neoplasia.

[3]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[4]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[5]  K. Yoshikawa,et al.  Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. , 2003, The Journal of investigative dermatology.

[6]  D. Gallahan,et al.  A novel non-mouse mammary tumor virus activation of the Int-3 gene in a spontaneous mouse mammary tumor , 1995, Journal of virology.

[7]  S. Schnitt,et al.  Expression of scatter factor and c‐met receptor in benign and malignant breast tissue , 1997 .

[8]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[9]  L. Buluwela,et al.  HGF/SF in Mammary Epithelial Growth and Morphogenesis: In Vitro and In Vivo Models , 2004, Journal of Mammary Gland Biology and Neoplasia.

[10]  A. Chambers,et al.  Osteopontin‐induced, integrin‐dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met) , 2000, Journal of cellular biochemistry.

[11]  R. Cardiff,et al.  Activation of β-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Birchmeier,et al.  Reconstitution of Mammary Gland Development In Vitro: Requirement of c-met and c-erbB2 Signaling for Branching and Alveolar Morphogenesis , 1998, The Journal of cell biology.

[13]  B. Elliott,et al.  The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. , 2002, Canadian journal of physiology and pharmacology.

[14]  Nakopoulou,et al.  c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinoma , 2000, Histopathology.

[15]  W. Birchmeier,et al.  Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland , 1995, The Journal of cell biology.

[16]  D. Rimm,et al.  Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.

[17]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[18]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[19]  M. Nemir,et al.  Targeted Inhibition of Osteopontin Expression in the Mammary Gland Causes Abnormal Morphogenesis and Lactation Deficiency* , 2000, The Journal of Biological Chemistry.

[20]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[21]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  L. Hennighausen,et al.  A milk protein gene promoter directs the expression of human tissue plasminogen activator cDNA to the mammary gland in transgenic mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[24]  G. V. Vande Woude,et al.  Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. V. Vande Woude,et al.  HGF/SF‐met signaling in the control of branching morphogenesis and invasion , 2003, Journal of cellular biochemistry.

[26]  T. Noda,et al.  Inactivation of Apc perturbs mammary development, but only directly results in acanthoma in the context of Tcf-1 deficiency , 2002, Oncogene.

[27]  B. Gusterson,et al.  In VivoEffects of Hepatocyte Growth Factor/Scatter Factor on Mouse Mammary Gland Development , 1998 .

[28]  P. Leder,et al.  β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland , 2001, Oncogene.